You need JavaScript to view this

Optimization of production and quality control of therapeutic radionuclides and radiopharmaceuticals. Final report of a co-ordinated research project 1994-1998

Abstract

The `renaissance` of the therapeutic applications of radiopharmaceuticals during the last few years was in part due to a greater availability of radionuclides with appropriate nuclear decay properties, as well as to the development of carrier molecules with improved characteristics. Although radionuclides such as {sup 32}P, {sup 89}Sr and {sup 131}I, were used from the early days of nuclear medicine in the late 1930s and early 1940s, the inclusion of other particle emitting radionuclides into the nuclear medicine armamentarium was rather late. Only in the early 1980s did the specialized scientific literature start to show the potential for using other beta emitting nuclear reactor produced radionuclides such as {sup 153}Sm, {sup 166} Ho, {sup 165}Dy and {sup 186-188}Re. Bone seeking agents radiolabelled with the above mentioned beta emitting radionuclides demonstrated clear clinical potential in relieving intense bone pain resulting from metastases of the breast, prostate and lung of cancer patients. Therefore, upon the recommendation of a consultants meeting held in Vienna in 1993, the Co-ordinated Research Project (CRP) on Optimization of the Production and quality control of Radiotherapeutic Radionuclides and Radiopharmaceuticals was established in 1994. The CRP aimed at developing and improving existing laboratory protocols for the production of therapeutic  More>>
Authors:
"NONE"
Publication Date:
Sep 01, 1999
Product Type:
Technical Report
Report Number:
IAEA-TECDOC-1114
Reference Number:
SCA: 550604; 560180; 550601; PA: AIX-30:045331; EDB-99:103322; SN: 99002154957
Resource Relation:
Other Information: DN: Refs, 53 tabs, 27 figs; PBD: Sep 1999
Subject:
55 BIOLOGY AND MEDICINE, BASIC STUDIES; 56 BIOLOGY AND MEDICINE, APPLIED STUDIES; COORDINATED RESEARCH PROGRAMS; DYSPROSIUM 165; HOLMIUM 166; IODINE 131; PHOSPHORUS 32; QUALITY ASSURANCE; QUALITY CONTROL; RADIATION PROTECTION; RADIOPHARMACEUTICALS; RADIOTHERAPY; RHENIUM 186; RHENIUM 187; RHENIUM 188; SAMARIUM 153; STRONTIUM 89
OSTI ID:
691154
Research Organizations:
International Atomic Energy Agency, Vienna (Austria)
Country of Origin:
IAEA
Language:
English
Other Identifying Numbers:
Journal ID: ISSN 1011-4289; Other: ON: DE99635805; TRN: XA9952512045331
Availability:
INIS; OSTI as DE99635805
Submitting Site:
INIS
Size:
100 p.
Announcement Date:

Citation Formats

Optimization of production and quality control of therapeutic radionuclides and radiopharmaceuticals. Final report of a co-ordinated research project 1994-1998. IAEA: N. p., 1999. Web.
Optimization of production and quality control of therapeutic radionuclides and radiopharmaceuticals. Final report of a co-ordinated research project 1994-1998. IAEA.
1999. "Optimization of production and quality control of therapeutic radionuclides and radiopharmaceuticals. Final report of a co-ordinated research project 1994-1998." IAEA.
@misc{etde_691154,
title = {Optimization of production and quality control of therapeutic radionuclides and radiopharmaceuticals. Final report of a co-ordinated research project 1994-1998}
abstractNote = {The `renaissance` of the therapeutic applications of radiopharmaceuticals during the last few years was in part due to a greater availability of radionuclides with appropriate nuclear decay properties, as well as to the development of carrier molecules with improved characteristics. Although radionuclides such as {sup 32}P, {sup 89}Sr and {sup 131}I, were used from the early days of nuclear medicine in the late 1930s and early 1940s, the inclusion of other particle emitting radionuclides into the nuclear medicine armamentarium was rather late. Only in the early 1980s did the specialized scientific literature start to show the potential for using other beta emitting nuclear reactor produced radionuclides such as {sup 153}Sm, {sup 166} Ho, {sup 165}Dy and {sup 186-188}Re. Bone seeking agents radiolabelled with the above mentioned beta emitting radionuclides demonstrated clear clinical potential in relieving intense bone pain resulting from metastases of the breast, prostate and lung of cancer patients. Therefore, upon the recommendation of a consultants meeting held in Vienna in 1993, the Co-ordinated Research Project (CRP) on Optimization of the Production and quality control of Radiotherapeutic Radionuclides and Radiopharmaceuticals was established in 1994. The CRP aimed at developing and improving existing laboratory protocols for the production of therapeutic radionuclides using existing nuclear research reactors including the corresponding radiolabelling, quality control procedures; and validation in experimental animals. With the participation of ten scientists from IAEA Member States, several laboratory procedures for preparation and quality control were developed, tested and assessed as potential therapeutic radiopharmaceuticals for bone pain palliation. In particular, the CRP optimised the reactor production of {sup 153}Sm and the preparation of the radiopharmaceutical {sup 153}Sm-EDTMP (ethylene diamine tetramethylene phosphonate), as well as radiolabelling techniques and quality control methods for the preparation of {sup 153}Sm-hydroxyapatite, {sup 153}Sm and {sup 166}Ho-microspheres and {sup 166}Ho-ferric-hydroxy-macro-aggregates for the treatment of rheumatoid arthritis. The laboratory protocols included in the report were developed and thoroughly assessed and tested by the participants during the course of the CRP. These procedures are considered effective as well as simple to follow by anyone wishing to embark on the production and preparation of the above therapeutic radionuclides and radiopharmaceuticals for bone pain palliation and synovectomy applications Refs, 53 tabs, 27 figs}
place = {IAEA}
year = {1999}
month = {Sep}
}